Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB): 6 pipeline candidates · ~7 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
7.1 months
D/E 3.44 · 0% dilution
Lead: Approved
6 candidates
N/A
0 buys · 8 sells (180d)
A transparent, data-derived signal for Seres Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$62.6M
Cash
$38.5M
Quarterly Burn
$16.4M
Runway
7.1 mo
Revenue
$358K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
34
Total value held
$24.7M
| Holder | Shares | Value |
|---|---|---|
| flagship pioneering, llc | 1,155,850 | $10.3M |
| vanguard capital management llc | 588,286 | $5.2M |
| susquehanna international group, llp | 226,939 | $2.0M |
| marshall wace, llp | 139,539 | $1.2M |
| vontobel holding ltd. | 138,468 | $1.2M |
| blackrock, inc. | 102,026 | $905K |
| geode capital management, llc | 74,835 | $664K |
| american century companies inc | 62,316 | $553K |
| citadel advisors llc | 59,500 | $528K |
| vanguard fiduciary trust co | 39,643 | $352K |
Showing top 10 of 34 institutional holders of Seres Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Seres Therapeutics, Inc.'s pipeline?
Seres Therapeutics, Inc. (MCRB) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Seres Therapeutics, Inc.'s lead drug candidate?
Seres Therapeutics, Inc.'s most advanced tracked candidate is SER-147 (Phase 1) for Prevention of bacterial bloodstream and spontaneous bacterial peritonitis (SBP) infections in patients with metabolic disease, including chronic liver disease (CLD).
What is Seres Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Seres Therapeutics, Inc. has approximately 7.1 months of cash runway.
What is Seres Therapeutics, Inc.'s market capitalization?
Seres Therapeutics, Inc.'s market capitalization is approximately $62.6M.
Who is the CEO of Seres Therapeutics, Inc.?
Mr. Richard N. Kender B.S., M.B.A. is the chief executive officer of Seres Therapeutics, Inc. (MCRB).
Get the full picture on Seres Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.